BEACON-IPF
Recruiting
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This phase 3 study will evaluate bexotograst in patients with IPF. The study will include a CT, PEs, lung function testing, EKGs, vital signs, questionnaires, and safety labs, as well as PK and PD testing.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 854855
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
